Home › Anaplastic Large-Cell Lymphoma
Pag-aaral pangklinika para sa Anaplastic Large-Cell Lymphoma na nagre-recruit sa U.S.
14 pag-aaral para sa Anaplastic Large-Cell Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX4 pag-aaral
- St. Louis, MO4 pag-aaral
- Atlanta, GA4 pag-aaral
- Durham, NC4 pag-aaral
- Rochester, MN4 pag-aaral
- Boston, MA3 pag-aaral
- Philadelphia, PA3 pag-aaral
- Seattle, WA3 pag-aaral
- Columbus, OH3 pag-aaral
- Baldwin Park, CA3 pag-aaral
- New York City, NY3 pag-aaral
Ayos sa estado
- Arizona3 pag-aaral
- California4 pag-aaral
- Florida3 pag-aaral
- Georgia4 pag-aaral
- Illinois3 pag-aaral
- Massachusetts3 pag-aaral
- Minnesota4 pag-aaral
- Missouri4 pag-aaral
- New Jersey3 pag-aaral
- New York5 pag-aaral
- North Carolina5 pag-aaral
- Ohio3 pag-aaral
- Pennsylvania4 pag-aaral
- Texas5 pag-aaral
- Washington3 pag-aaral
- Wisconsin3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Nagre-recruitPhase 1
Edad 12 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06176690A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Nagre-recruitPhase 1/2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04094610Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06724237Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07750886Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06508463Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT03017820Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
6 Months · Lahat ng kasarian · Na-update May 29, 2026 · NCT04195633A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 26, 2026 · NCT07001384A Registry for People With T-cell Lymphoma
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Nagre-recruitPhase 2
Edad 1 hanggang 39 · Lahat ng kasarian · Na-update May 20, 2026 · NCT07013565Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 3, 2026 · NCT05544968Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.